当前位置: X-MOL 学术Restor. Neurol. Neurosci. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prestroke statin use enhances collateralization in acute ischemic stroke patients.
Restorative Neurology and Neuroscience ( IF 2.8 ) Pub Date : 2020-09-09 , DOI: 10.3233/rnn-201012
Jiaying Zhu 1, 2 , Mengmeng Ma 1 , Jinghuan Fang 1 , Jiajia Bao 1 , Shuju Dong 1 , Ning Chen 1 , Yijia Guo 1 , Li He 1
Affiliation  

Background:Statin therapy has been shown to be effective in the prevention of ischemic stroke. In addition, recent studies have suggested that prior statin therapy could lower the initial stroke severity and improve stroke functional outcomes in the event of stroke. It was speculated that prestrokestatin use may enhance collateral circulation and result in favorable functional outcomes. Objective:The aim of the study was to investigate the association of prestroke statin use with leptomeningeal collaterals and to determine the association of prestroke statin use with stroke severity and functional outcome in acute ischemic stroke patients. Methods:We prospectively and consecutively enrolled 239 acute ischemic stroke patients with acute infarction due to occlusion of the middle cerebral artery within 24 h in the neurology department of West China Hospital from May 2011 to April 2017. Computed tomographic angiography (CTA) imaging was performed for all patients to detect middle cerebral artery thrombus; regional leptomeningeal collateral score (rLMCS) was used to assess the degree of collateral circulation; the National Institutes of Health Stroke Scale (NIHSS) was used to measure stroke severity at admission; the modified Rankin scale (mRS) was used to measure outcome at 90 days; and premorbid medications were recorded. Univariate and multivariate analyses were performed. Results:Overall, 239 patients met the inclusion criteria. Fifty-four patients used statins, and 185 did not use statins before stroke onset. Prestroke statin use was independently associated with good collateral circulation (rLMCS > 10) (odds ratio [OR], 4.786; 95% confidence interval [CI], 1.195–19.171; P = 0.027). Prestroke statin use was not independently associated with lower stroke severity (NIHSS score≤14) (OR, 1.955; 95% CI, 0.657–5.816; p = 0.228), but prestroke statin use was independently associated with favorable outcome (mRS score≤2) (OR, 3.868; 95% CI, 1.325–11.289; P = 0.013). Conclusions:Our findings suggest that prestroke statin use was associated with good leptomeningeal collaterals and clinical outcomes in acute ischemic stroke (AIS) patients presenting with occlusion of the middle cerebral artery. However, clinical studies should be conducted to verify this claim.

中文翻译:

中风前他汀类药物的使用可增强急性缺血性中风患者的侧支作用。

背景:他汀类药物疗法已证明可有效预防缺血性中风。此外,最近的研究表明,先前的他汀类药物治疗可降低中风的初始程度,并在中风时改善中风的功能结局。据推测,使用中风他汀可能会促进侧支循环并导致良好的功能预后。目的:研究目的是研究急性缺血性中风患者中风前他汀类药物与软脑膜侧支的关系,并确定中风前他汀类药物与中风严重程度和功能预后的关系。方法:我们从2011年5月至2017年4月在华西医院神经内科前瞻性并连续入组239例因大脑中动脉闭塞而导致的急性缺血性脑卒中患者,时间为24小时。对所有患者均进行了计算机断层造影患者发现大脑中动脉血栓;使用区域性脑膜旁侧旁支评分(rLMCS)评估侧支循环程度;美国国立卫生研究院卒中量表(NIHSS)用于衡量入院时的卒中严重程度;修改后的兰金量表(mRS)用于评估90天时的结局;并记录病前药物。进行了单因素和多因素分析。结果:总体上有239例患者符合纳入标准。54名患者使用他汀类药物,185名中风发作前未使用他汀类药物。中风前他汀类药物的使用与良好的侧支循环独立相关(rLMCS> 10)(几率[OR]为4.786; 95%置信区间[CI]为1.195-19.171; P = 0.027)。中风前他汀类药物的使用并不独立于卒中严重程度较低(NIHSS评分≤14)(OR,1.955; 95%CI,0.657–5.816; p = 0.228),但中风前他汀类药物的使用与良好的预后独立相关(mRS评分≤2 )(OR为3.868; 95%CI为1.325-11.289; P = 0.013)。结论:我们的研究结果表明,卒中前他汀类药物的使用与伴有大脑中动脉闭塞的急性缺血性卒中(AIS)患者良好的软脑膜侧支和临床结局相关。但是,应进行临床研究以验证这一主张。中风前他汀类药物的使用与良好的侧支循环独立相关(rLMCS> 10)(几率[OR]为4.786; 95%置信区间[CI]为1.195-19.171; P = 0.027)。中风前他汀类药物的使用并不独立于卒中严重程度较低(NIHSS评分≤14)(OR,1.955; 95%CI,0.657–5.816; p = 0.228),但中风前他汀类药物的使用与良好的预后独立相关(mRS评分≤2 )(OR为3.868; 95%CI为1.325-11.289; P = 0.013)。结论:我们的研究结果表明,卒中前他汀类药物的使用与伴有大脑中动脉闭塞的急性缺血性卒中(AIS)患者良好的软脑膜侧支和临床结局相关。但是,应进行临床研究以验证这一主张。中风前他汀类药物的使用与良好的侧支循环独立相关(rLMCS> 10)(几率[OR]为4.786; 95%置信区间[CI]为1.195-19.171; P = 0.027)。中风前他汀类药物的使用并不独立于卒中严重程度较低(NIHSS评分≤14)(OR,1.955; 95%CI,0.657–5.816; p = 0.228),但中风前他汀类药物的使用与良好的预后独立相关(mRS评分≤2 )(OR为3.868; 95%CI为1.325-11.289; P = 0.013)。结论:我们的研究结果表明,卒中前他汀类药物的使用与伴有大脑中动脉闭塞的急性缺血性卒中(AIS)患者良好的软脑膜侧支和临床结局相关。但是,应进行临床研究以验证这一主张。95%置信区间[CI],1.195-19.171;P = 0.027)。中风前他汀类药物的使用并不独立于卒中严重程度较低(NIHSS评分≤14)(OR,1.955; 95%CI,0.657–5.816; p = 0.228),但中风前他汀类药物的使用与良好的预后独立相关(mRS评分≤2 )(OR为3.868; 95%CI为1.325-11.289; P = 0.013)。结论:我们的研究结果表明,卒中前他汀类药物的使用与伴有大脑中动脉闭塞的急性缺血性卒中(AIS)患者良好的软脑膜侧支和临床结局相关。但是,应进行临床研究以验证这一主张。95%置信区间[CI],1.195-19.171;P = 0.027)。中风前他汀类药物的使用并不独立于卒中严重程度较低(NIHSS评分≤14)(OR,1.955; 95%CI,0.657–5.816; p = 0.228),但中风前他汀类药物的使用与良好的预后独立相关(mRS评分≤2 )(OR为3.868; 95%CI为1.325-11.289; P = 0.013)。结论:我们的研究结果表明,卒中前他汀类药物的使用与伴有大脑中动脉闭塞的急性缺血性卒中(AIS)患者良好的软脑膜侧支和临床结局相关。但是,应进行临床研究以验证这一主张。但是中风前他汀类药物的使用与预后良好相关(mRS评分≤2)(OR,3.868; 95%CI,1.325-11.289; P = 0.013)。结论:我们的研究结果表明,卒中前他汀类药物的使用与伴有大脑中动脉闭塞的急性缺血性卒中(AIS)患者良好的软脑膜侧支和临床结局相关。但是,应进行临床研究以验证这一主张。但是中风前他汀类药物的使用与预后良好相关(mRS评分≤2)(OR,3.868; 95%CI,1.325-11.289; P = 0.013)。结论:我们的研究结果表明,卒中前他汀类药物的使用与伴有大脑中动脉闭塞的急性缺血性卒中(AIS)患者良好的软脑膜侧支和临床结局相关。但是,应进行临床研究以验证这一主张。
更新日期:2020-09-12
down
wechat
bug